Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Blood (2014) 123 (21): 3247–3254.

https://doi.org/10.1182/blood-2014-01-546150

Published: 2014

Includes: Supplemental data

Journal Articles

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Billy Michael Chelliah Jebaraj, PhD, Raymonde Busch, PhD, Thorsten Zenz, MD, Andreas Bühler, MD, Dirk Winkler, MD, Andrea Schnaiter, MD, Jennifer Edelmann, MD, Daniel Mertens, PhD, Sebastian Böttcher, MD, Michael Kneba, MD, Ulrich Jäger, MD, Michael K Wenger, MD, Guenter Fingerle-Rowson, MD PhD, Clemens Wendtner, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 671.

https://doi.org/10.1182/blood.V122.21.671.671

Published: 2013

Journal Articles

NOTCH1 , SF3B1 , and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

Andrea Schnaiter, Peter Paschka, Marianna Rossi, Thorsten Zenz, Andreas Bühler, Dirk Winkler, Mario Cazzola, Konstanze Döhner, Jennifer Edelmann, Daniel Mertens, Sabrina Kless, Silja Mack, Raymonde Busch, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer

Blood (2013) 122 (7): 1266–1270.

https://doi.org/10.1182/blood-2013-03-488197

Published: 2013

Includes: Supplemental data

Journal Articles

High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations

Blood (2012) 120 (24): 4783–4794.

https://doi.org/10.1182/blood-2012-04-423517

Published: 2012

Includes: Supplemental data

Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood (2012) 120 (21): 433.

https://doi.org/10.1182/blood.V120.21.433.433

Published: 2012

Journal Articles

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW

Blood (2012) 120 (21): 716.

https://doi.org/10.1182/blood.V120.21.716.716

Published: 2012

Journal Articles

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial

Blood (2012) 119 (21): 4851–4859.

https://doi.org/10.1182/blood-2011-09-378505

Published: 2012

Includes: Supplemental data

Journal Articles

Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG)

Dirk Winkler, MD, Raymonde Busch, Andreas Buehler, MD, Michael K. Wenger, MD, Kirsten Fischer, MD, Anna-Maria Fink, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2011) 118 (21): 2841.

https://doi.org/10.1182/blood.V118.21.2841.2841

Published: 2011

Journal Articles

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Anna Fink, MD, Raymonde Busch, Natali Pflug, MD, Sebastian Boettcher, MD, Dirk Winkler, MD, Andreas Buehler, MD, Matthias Ritgen, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Myriam Mendila, MD, Michael K. Wenger, MD, Hartmut Doehner, MD, Michael Kneba, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD

Blood (2011) 118 (21): 977.

https://doi.org/10.1182/blood.V118.21.977.977

Published: 2011

Journal Articles

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

Sebastian Boettcher, MD, Matthias Ritgen, MD, Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Raymonde Busch, Gunter R. Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Andreas Buehler, MD, Dirk Winkler, MD, Michael K. Wenger, MD, Myriam Mendila, MD, Clemens Wendtner, MD, Barbara Eichhorst, MD, Hartmut Döhner, MD, Michael Hallek, MD, Michael Kneba, MD

Blood (2011) 118 (21): 1777.

https://doi.org/10.1182/blood.V118.21.1777.1777

Published: 2011

Journal Articles

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW

Blood (2011) 118 (21): 2854.

https://doi.org/10.1182/blood.V118.21.2854.2854

Published: 2011

Journal Articles

DNA damage–induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing

Julia Mohr, Hanne Helfrich, Maxi Fuge, Eric Eldering, Andreas Bühler, Dirk Winkler, Matthias Volden, Arnon P. Kater, Daniel Mertens, Doreen Te Raa, Hartmut Döhner, Stephan Stilgenbauer, Thorsten Zenz

Blood (2011) 117 (5): 1622–1632.

https://doi.org/10.1182/blood-2010-08-300160

Published: 2011

Includes: Supplemental data

Journal Articles

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Anna Fink, MD, Natali Pflug, MD, Raymonde Busch, Gunter R. Fingerle-Rowson, MD, PhD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Dirk Winkler, MD, Andreas Buehler, MD, Myriam Mendila, MD, Michael Wenger, MD, Hartmut Dohner, MD, Stephan Stilgenbauer, M.D., Michael Hallek, MD, Kirsten Fischer, MD

Blood (2010) 116 (21): 918.

https://doi.org/10.1182/blood.V116.21.918.918

Published: 2010

Journal Articles

Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine – Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW

Blood (2010) 116 (21): 920.

https://doi.org/10.1182/blood.V116.21.920.920

Published: 2010

Journal Articles

IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)

Andreas Bühler, MD, Thorsten Zenz, MD, Dirk Winkler, MD, Raymonde Busch, Kirsten Fischer, MD, Anna Fink, MD, Clemens Wendtner, Barbara Eichhorst, Jennifer Edelmann, MD, Michael Hallek, Hartmut Doehner, MD, Stephan Stilgenbauer, M.D.

Blood (2010) 116 (21): 3609.

https://doi.org/10.1182/blood.V116.21.3609.3609

Published: 2010

Journal Articles

High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia

Jennifer Edelmann, MD, Karlheinz Holzmann, PhD, W.M. Michael Kühn, MD, Lars Bullinger, MD, Ina Radtke, MD, PhD, Xiaoping Su, PhD, Jing Ma, Ph.D., Dirk Winkler, MD, Andreas Buehler, Michael Hallek, M.D., James R. Downing, MD, Stephan Stilgenbauer, MD, Hartmut Doehner, MD

Blood (2010) 116 (21): 50.

https://doi.org/10.1182/blood.V116.21.50.50

Published: 2010

Journal Articles

Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

Thorsten Zenz, MD, Peter Dreger, MD, PhD, Sascha Dietrich, MD, Sebastian Böttcher, MD, Matthias Ritgen, MD, Dirk Winkler, MD, Andreas Bühler, MD, Donald Bunjes, MD, Dietrich Beelen, MD, Sandra Cohen, MD, FRCPC, Ute Hegenbart, MD, Matthias Zeis, MD, Michael Hallek, M.D., Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, M.D.

Blood (2010) 116 (21): 2357.

https://doi.org/10.1182/blood.V116.21.2357.2357

Published: 2010

Journal Articles

Exceptional In Vitro Activity of CD37 Antibodies In CLL

Thorsten Zenz, MD, Matthias Volden, Theresa Mast, Karsten Nordhausen, Dirk Winkler, MD, Andrea Schnaiter, MD, Andreas Buehler, MD, Karl-Heinz Heider, PhD, Volker Reichardt, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2010) 116 (21): 2460.

https://doi.org/10.1182/blood.V116.21.2460.2460

Published: 2010

Journal Articles

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

Thorsten Zenz, MD, Raymonde Busch, Anna Fink, MD, Dirk Winkler, MD, Kirsten Fischer, MD, Andreas Bühler, MD, Patrick Hoth, Gunter R. Fingerle-Rowson, MD, PhD, Michael Kneba, MD, PhD, Sebastian Boettcher, MD, Ulrich Jäger, MD, Myriam Mendila, MD, Michael Wenger, MD, Peter Lichter, PhD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2010) 116 (21): 2427.

https://doi.org/10.1182/blood.V116.21.2427.2427

Published: 2010

Journal Articles

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Blood (2010) 116 (14): 2438–2447.

https://doi.org/10.1182/blood-2010-03-275420

Published: 2010

Includes: Supplemental data

NARROW

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

NOTCH1 , SF3B1 , and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial

Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG)

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW

DNA damage–induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine – Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW

IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)

High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia

Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

Exceptional In Vitro Activity of CD37 Antibodies In CLL

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only